[Clinical Medicine Insights: Oncology] Cancer cachexia affects many advanced non-small-cell lung cancer (NSCLC) patients.
Validation study of the modified injection technique for internal mammary sentinel lymph node biopsy in breast cancerOctober 09, 2015
[OncoTargets and Therapy] According to the hypothesis of internal mammary sentinel lymph node, lymphatic drainage pattern, a modified radiotracer injection technique was established.
[Clinical Medicine Insights: Oncology] Although myelosuppression is the most adverse event of this therapy, gemcitabine might induce severe pulmonary toxicities.
[Blood and Lymphatic Cancer Targets and Therapy] Imatinib was the first tyrosine kinase inhibitor (TKI), successfully used in a clinical setting.
[Clinical Medicine Insights: Oncology] Given the absence of association between multiple sclerosis, diffuse large B-cell lymphoma, causal association with natalizumab cannot be excluded.
[Cancer Control] Molecular testing is entrenched in the workup and management of hematological malignancies.
[Translational Lung Cancer Research] This research investigates the prevalence and clinicopathological features of BRAF mutations in non-small cell lung cancer (NSCLC) cases submitted for routine mutation testing.
[Biomarkers in Cancer] Cluster of differentiation 151 (CD151) functions at various stages of cancer, including metastatic cascade and primary tumor growth, reinforcing the importance of CD151 as a target in oncology.
[Breast Cancer: Targets and Therapy] This review focuses on the role of the WASP/WAVE family in breast cancer cell invasion and migration.
Threading the cloak: palliative care education for care providers of adolescents, young adults with cancerMay 07, 2015
[Clinical Oncology in Adolescents and Young Adults] Integration of palliative care at the time of diagnosis enables a supportive partnership with the medical team.
Internalization: Acute apoptosis of breast cancer cells using herceptin-immobilized gold nanoparticlesApril 17, 2015
[Breast Cancer: Targets and Therapy] Gold nanoparticles (GNPs) can be used in the imaging of tumors, as delivery agents for antitumor drugs, and for nonaggressive amputation treatments.
[Cancer Control] Platelet transfusion can often be a vital aspect aspect of managing cancer, as treatment courses can weaken the function of the cells requires to stop bleeding.
[Breast Cancer: Basic and Clinical Research] This case study examines a rare occurrence of adenoid cystic carcinoma (ACC) in a 19-year-old woman.
Intraperitoneal Follicular Dendritic Cell Sarcoma: Role of Chemotherapy and Bone Marrow Allotransplantation in Locally Advanced Disease?February 27, 2015
[Clinical Medicine Insights: Oncology] Intraperitoneal location of follicular dendritic cell sarcoma (FDCS) is very uncommon and is associated with a particularly aggressive clinical course.
[Cancer Management and Research] Axitinib is approved for use in the second-line setting for patients with metastatic renal cell carcinoma.
[Translational Cancer Research] Intraoperative radiotherapy (IORT) has emerged as a technique to deliver a single high dose of radiation to a target volume at the time of an operation.
[Cancer Control] New developments in metastatic castration-resistant prostate cancer (mCRPC) have resulted in several new therapies.
[Blood and Lymphatic Cancer: Targets and Therapy] Myeloma displays considerable heterogeneity and, over time, control of disease can be lost. New strategies to combat myeloma incorporate risk stratification to provide more individualized therapy.
[Clinical Medicine Insights: Oncology] Performance status is the only known clinical predictor of outcome in patients with advanced non-small-cell lung cancer (NSCLC), but pharmacogenomic markers may also correlate with outcome. This study attempts to correlate clinical and pharmacogenomic measures with overall survival.
[Journal of Gastrointestinal Oncology] This study examines outcomes of CEC patients treated with CRT and the incidence and potential role of HPV tumor infection in CEC lesions.
Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnosticsDecember 10, 2014
[Lung Cancer: Targets and Therapy] The appropriate role of EGFR mutation analysis in the treatment of patients with NSCLC is constantly evolving; EGFR mutation testing can help simplify the drug discovery process and individualize cancer therapy.
[Cancer Control] Castleman disease is a lesser seen lymphoproliferative disorder, which is characterized as either localized or multicentric, with differing treatments typically utilized for each type.
[Cancer Informatics] When examined, cancer comorbidities can reveal valuable clues to understanding the underlying genetic mechanisms of cancers. The comorbidity patterns among different patient groups and the effect of age and gender on cancer comorbidity patterns are investigated.
[Cancer Management and Research] Although thin melanomas have an excellent prognosis after sufficient surgical treatment, melanoma disease in advanced stages still proves to be a therapeutic challenge.
[Clin Med Insights Oncol] HPV is a risk factor for anal intraepithelial neoplasia (AIN). Etiology, anatomy, pathogenesis, management of squamous cell carcinoma (SCC) discussed.
[Breast Cancer (Auckl)] Human epidermal growth factor receptor-2 is overexpressed in up to 30% of breast cancers; indicative of poor prognosis.
[Cancer Control] Immunotherapeutic approaches to treating cancer have been evaluated during the last few decades with limited success.
[Biomark Cancer] Biomarkers can provide great opportunities in the management of the most common HIV-associated malignancies, namely, Kaposi sarcoma, non-Hodgkin's lymphoma, and invasive cervical cancer.
FDG-PET/CT in the Assessment of Treatment Response after Oncologic Treatment of Head and Neck Squamous Cell CarcinomaAugust 29, 2014
[Clin Med Insights Ear Nose Throat] FDG-PET/CT is used to monitor treatment response after definitive (chemo)radiotherapy for head and neck squamous cell carcinoma, but its usefulness remains controversial.
[Lymphoma and Chronic Lymphocytic Leukemias] Biomarker-driven chemotherapeutics is becoming a critical part of the state-of-the-art treatment in clinical trials involving patients with T-cell lymphoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?